BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies-Reference-Cited by-同舟云学术

BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies

Published:2021-08-24 Issue:17 Volume:64 Page:12723-12737
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Berger Markus¹^ORCID,Wortmann Lars¹^ORCID,Buchgraber Philipp¹,Lücking Ulrich¹^ORCID,Zitzmann-Kolbe Sabine¹,Wengner Antje M.¹,Bader Benjamin¹,Bömer Ulf¹,Briem Hans¹,Eis Knut¹^ORCID,Rehwinkel Hartmut¹,Bartels Florian¹,Moosmayer Dieter¹,Eberspächer Uwe¹,Lienau Philip¹,Hammer Stefanie¹,Schatz Christoph A.¹,Wang Qiuwen²,Wang Qi³,Mumberg Dominik¹,Nising Carl F.¹^ORCID,Siemeister Gerhard¹

Affiliation:

1. Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany

2. Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China

3. WuXi AppTec (Wuhan) Co., Ltd., 666 Gaoxin Road, East Lake High-tech Development Zone, Wuhan 430075, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00762

Reference31 articles.

1. Instability and decay of the primary structure of DNA